clinical trial · NCT03457532
A Phase I Study of SCC244 in Patients with Advanced MET Alterations Solid Tumors
Haihe Biopharma Co., Ltd.·phase1·completed·n = 177
Advanced Solid TumorGumarontinib Tablets
brief summary
This is a Phase 1a/1b multi-center and open label study to evaluate the safety, tolorability, pharmacokinetics and priliminary efficacy of SCC244 in advanced solid tumors patients with c-MET alteration
started
Dec 16, 2017
primary completion
Sep 22, 2023
completion
Sep 22, 2023
last updated
Nov 1, 2024
detailed description
This is a phase I study, its purpose to evaluate the safety and tolerability and to determine the maximum tolerated dose (MTD)/ biologically effective dose (BED) and the recommended phase II dose (RP2D) of SCC244 monotherapy in patients with advanced MET alterations solid tumors;
official title
An Open-label, Multicenter, Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics Characters, and Preliminary Efficacy of SCC244 in Patients with Advanced MET Alterations Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol